Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey Weber

Showing results (31-40 of 104) with videos related to

Pageof 11
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 20, 2013
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--letterLaszlo Radvanyi, Shari Pilon-Thomas, Weiyi Peng, et al.
Frontiers in Oncology|February 6, 2023
A genome-wide association study of germline variation and melanoma prognosisVylyny Chat, Sasha Dagayev, Una Moran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2005
Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory studyDongxin Liu, Steven J O'Day, Dongyun Yang, et al.
Cancer Medicine|October 14, 2021
Preexisting immune-mediated inflammatory disease is associated with improved survival and increased toxicity in melanoma patients who receive immune checkpoint inhibitorsNicholas Gulati, Arda Celen, Paul Johannet, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 8, 2005
Rapid assessment of recognition efficiency and functional capacity of antigen-specific T-cell responsesHolbrook E Kohrt, Chen-Tsen Shu, Tor B Stuge, et al.
Journal for Immunotherapy of Cancer|August 21, 2019
The complex relationship between body mass index and response to immune checkpoint inhibition in metastatic melanoma patientsDouglas Donnelly, Shirin Bajaj, Jaehong Yu, et al.
Cancer|July 12, 2005
CCI-779 in metastatic melanoma: a phase II trial of the California Cancer ConsortiumKim Margolin, Jeffrey Longmate, Tracey Baratta, et al.
Cancer Immunity|November 25, 2010
Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanomaDavid Berman, Susan M Parker, Jonathan Siegel, et al.
Cancer Investigation|August 17, 2005
A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSFKarl D Lewis, Peter Gibbs, Steven O'Day, et al.
Clinical Mass Spectrometry (Del Mar, Calif.)|November 25, 2021
A proposal for score assignment to characterize biological processes from mass spectral analysis of serumJoanna Roder, Lelia Net, Carlos Oliveira, et al.
Pageof 11

Showing results (31-40 of 104) with videos related to

Sort By:
Pageof 11
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 20, 2013
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--letterLaszlo Radvanyi, Shari Pilon-Thomas, Weiyi Peng, et al.
Frontiers in Oncology|February 6, 2023
A genome-wide association study of germline variation and melanoma prognosisVylyny Chat, Sasha Dagayev, Una Moran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2005
Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory studyDongxin Liu, Steven J O'Day, Dongyun Yang, et al.
Cancer Medicine|October 14, 2021
Preexisting immune-mediated inflammatory disease is associated with improved survival and increased toxicity in melanoma patients who receive immune checkpoint inhibitorsNicholas Gulati, Arda Celen, Paul Johannet, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 8, 2005
Rapid assessment of recognition efficiency and functional capacity of antigen-specific T-cell responsesHolbrook E Kohrt, Chen-Tsen Shu, Tor B Stuge, et al.
Journal for Immunotherapy of Cancer|August 21, 2019
The complex relationship between body mass index and response to immune checkpoint inhibition in metastatic melanoma patientsDouglas Donnelly, Shirin Bajaj, Jaehong Yu, et al.
Cancer|July 12, 2005
CCI-779 in metastatic melanoma: a phase II trial of the California Cancer ConsortiumKim Margolin, Jeffrey Longmate, Tracey Baratta, et al.
Cancer Immunity|November 25, 2010
Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanomaDavid Berman, Susan M Parker, Jonathan Siegel, et al.
Cancer Investigation|August 17, 2005
A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSFKarl D Lewis, Peter Gibbs, Steven O'Day, et al.
Clinical Mass Spectrometry (Del Mar, Calif.)|November 25, 2021
A proposal for score assignment to characterize biological processes from mass spectral analysis of serumJoanna Roder, Lelia Net, Carlos Oliveira, et al.
Pageof 11